NCT03278522View on ClinicalTrials.gov

Ramosetron Pre-treatment for PONV and QT Prolongation

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
PONVProlonged QTc Interval
Interventions
DRUG

Ramosetron

Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery

Trial Locations (1)

05030

Lee Sung Ho, Seoul

All Listed Sponsors
lead

Konkuk University Medical Center

OTHER

NCT03278522 - Ramosetron Pre-treatment for PONV and QT Prolongation | Biotech Hunter | Biotech Hunter